Nasdaq: LRMR/Biotechnology
Larimar Therapeutics, Inc.
Bala Cynwyd, PA, United States
Company overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.